β-adrenergic Blocker and a COX2 Inhibitor for Prevention of Colorectal Cancer Recurrence

• magnitude and duration of surgically induced immune depression, as reflected in the blood samples [ Time Frame: early postoperative ] [ Designated as safety issue: No ]
• Early postoperative morbidity and mortality [ Time Frame: 30 days ] [ Designated as safety issue: Yes ]

Colon and rectal cancer is the second most prevalent malignant disease in the western world, causing significant morbidity, mortality, and healthcare sources use. Treating colon and rectal cancer with curative intent generally includes resection of the primary tumor. Despite its crucial role, surgery by itself induce physiological changes resulting in significant immune depression and other physiological perturbations, which may in turn play a significant role in the initiation of new metastases and the progression of pre-existing dormant metastases. The aim of this study is to assess the use of perioperative medical intervention using a combination of a β-adrenergic blocker (Propranolol) and a COX2 inhibitor (Etodolac), in order to attenuate the surgically induced immunosuppression and other physiological perturbations, aiming to reduce the rate of tumor recurrence and distant metastatic disease.

• Active Comparator: 1
  Perioperative Propranolol and Etodolac
  Intervention: Drug: Propranolol and Etodolac
• Placebo Comparator: 2
  Placebo
  Intervention: Drug: Propranolol and Etodolac

Inclusion Criteria:

• Patients planned for surgery for primary resection of colon and rectal cancer in curative intent.
• Single colonic or rectal carcinoma, proofed by full colonoscopy and tumor biopsy. If colonoscopy failed to reach the cecum, proximal colonic investigation will be made using contract enema or CT colonography.
• No evidence of metastatic disease prior to surgery. Minimal workup would include abdominal CT with IV contrast (or CT+liver US) and chest XR.
• Age between 18 and 75 year old.
• ASA score of 1-3
• The patient is able to understand the study objectives and procedures, able to comply with the protocol, and is capable to sign an informed consent.

Exclusion Criteria:

• Patients with metastatic disease, known prior to surgery.
• Patients in whom metastatic disease is found at surgery will complete the intervention phase, followed for additional month for potential complications, and will exit the study to allow potential participation in further clinical trials.
• Patients in whom surgical resection is planned without curative intent.
• Patients with renal failure, measured by Creatinine level >1.5
• Patients with significant heart failure (NYH 3 or higher)
• Patients with significant liver failure (known cirrhosis, Bilirubin level>2)
• Patients suffering from asthma
• Patients with known allergy to one or more of the study medications
• Patients with known allergy to any medication from the non-steroidal anti-inflammatory drug group.
• Patients with diabetes (type 1 or 2).
• Patients treated chronically with one or more of the study medications
• Patients treated chronically with any type of Beta adrenergic blocker.
• Patients treated chronically with any type of COX inhibitor.
• Patients with second or third degree AV block.
• Patients with sinus bradycardia (patients with heart rate of less than 50).
• Patients with sick sinus syndrome.
• Patients with Prinzmetal's angina
• Patients with right sided heart failure owing to pulmonary hypertension.
• Patients with significant cardiomegaly
• Patients with (current) pheochromocytoma
• Patients with chronic Digoxin treatment
• Patients with active peptic disease
• Patients with peripheral vascular disease
• Patients with history or concomitant malignant disease of any type.
• Patients who were treated with chemotherapy in the last 10 years for any reason besides neo-adjuvant therapy for rectal cancer within the last six months.
• Pregnant woman.
• Patients participating in any other clinical trial

• Tel-Aviv Sourasky Medical Center
• Rabin Medical Center